Tesamorelin in Growth Research requires traceable specification (5mg / 10mg) and RUO acknowledgment; Tesamorelin Specification and Vial Format Review outlines buyer steps on sulanpeptide.vip.
Tesamorelin is a synthetic GHRH analog peptide used in laboratory research on growth-hormone-axis signaling, GHRH receptor pathway models, and peptide structure-activity studies.
Tesamorelin is a stabilized GHRH analog (trans-3-hexenoic acid modified) studied for pulsatile GH release and IGF-1 kinetics in human pituitary research models. Research compares tesamorelin against GHRH(1-44) in receptor binding and GH secretagogue potency assays.
GH peak area under curve after IV bolus in primate models and GHRH receptor cAMP dose–response curves support pharmacology characterization. FDA-reviewed research literature for tesamorelin focused on GH axis activation metrics in HIV-associated lipodystrophy research cohorts as endpoint biomarkers.
Principal investigators should sign off Tesamorelin SKUs only after mechanism fit is documented in the study protocol. Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Side-by-side review of specification table, vial label, and COA prevents release errors for Tesamorelin.
Catalog identifiers for Tesamorelin: CAS 218949-48-5, Formula: C221H366N72O67S. MW 5135.9 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for Tesamorelin to support reproducibility.
Dose planning for Tesamorelin should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Specification alignment for Tesamorelin requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for Tesamorelin—CAS 218949-48-5, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Tesamorelin should include these fields for reproducibility in Growth Research journals.
Format selection for Tesamorelin affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Tesamorelin. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Tesamorelin should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Tesamorelin. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Tesamorelin should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Format selection for Tesamorelin affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Tesamorelin should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type. Specification alignment for Tesamorelin requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for Tesamorelin—CAS 218949-48-5, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Tesamorelin should include these fields for reproducibility in Growth Research journals. Format selection for Tesamorelin affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Tesamorelin. QA sign-off should reference all four documents in the batch record.
Tesamorelin from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.